Equities research analysts forecast that Ligand Pharmaceuticals Inc. (NASDAQ:LGND) will announce $25.26 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Ligand Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $24.42 million and the highest estimate coming in at $26.09 million. Ligand Pharmaceuticals posted sales of $59.59 million during the same quarter last year, which would indicate a negative year over year growth rate of 57.6%. The firm is expected to report its next earnings results on Thursday, February 6th.
On average, analysts expect that Ligand Pharmaceuticals will report full year sales of $118.54 million for the current fiscal year, with estimates ranging from $117.70 million to $119.37 million. For the next fiscal year, analysts anticipate that the firm will post sales of $125.33 million, with estimates ranging from $121.25 million to $129.40 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Ligand Pharmaceuticals.
Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported $0.49 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.12). The business had revenue of $24.81 million during the quarter, compared to analysts’ expectations of $22.49 million. Ligand Pharmaceuticals had a return on equity of 7.47% and a net margin of 388.69%. The business’s revenue was down 45.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.32 EPS.
Shares of NASDAQ LGND opened at $108.00 on Monday. The company has a current ratio of 33.15, a quick ratio of 32.96 and a debt-to-equity ratio of 0.75. Ligand Pharmaceuticals has a 12 month low of $84.45 and a 12 month high of $154.37. The firm has a market capitalization of $1.90 billion, a PE ratio of 17.20, a price-to-earnings-growth ratio of 2.60 and a beta of 1.27. The firm has a fifty day simple moving average of $109.33 and a two-hundred day simple moving average of $105.57.
Large investors have recently added to or reduced their stakes in the company. Voloridge Investment Management LLC increased its position in Ligand Pharmaceuticals by 27.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 34,889 shares of the biotechnology company’s stock valued at $3,473,000 after buying an additional 7,407 shares in the last quarter. Granahan Investment Management Inc. MA grew its stake in shares of Ligand Pharmaceuticals by 17.2% in the third quarter. Granahan Investment Management Inc. MA now owns 20,556 shares of the biotechnology company’s stock worth $2,046,000 after acquiring an additional 3,015 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Ligand Pharmaceuticals during the third quarter valued at $222,000. Catalyst Capital Advisors LLC bought a new position in shares of Ligand Pharmaceuticals during the third quarter valued at $796,000. Finally, Boston Advisors LLC raised its position in shares of Ligand Pharmaceuticals by 60.9% in the 3rd quarter. Boston Advisors LLC now owns 10,829 shares of the biotechnology company’s stock worth $1,078,000 after purchasing an additional 4,097 shares during the last quarter.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.